| Literature DB >> 28575049 |
Christina Timm1, Bettina Ubl1, Vera Zamoscik2, Ulrich Ebner-Priemer3,4, Iris Reinhard5, Silke Huffziger1,4, Peter Kirsch2, Christine Kuehner1.
Abstract
BACKGROUND: Major depressive disorder (MDD) is characterized by a high risk for relapses and chronic developments. Clinical characteristics such as residual symptoms have been shown to negatively affect the long-term course of MDD. However, it is unclear so far how trait repetitive negative thinking (RNT) as well as cognitive and affective momentary states, the latter experienced during daily-life, affect the long-term course of MDD.Entities:
Mesh:
Year: 2017 PMID: 28575049 PMCID: PMC5456349 DOI: 10.1371/journal.pone.0178759
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study design.
Baseline predictors. (B) Diagnostic information to define outcome variables. BDI-II BeckDepressionInventory II. MADRS Montgomery and Asberg Depression Rating Scale. SCID-I Structured Clinical Interview for DSM-IV Axis 1.
Demographic, clinical, cognitive trait and affective and cognitive state characteristics in remitted depressed patients (rMDD) at baseline.
| rMDD (n = 57) | ||
|---|---|---|
| Mean (SD) / % | Range (min–max) | |
| age (SD) | 43 (10.3) | (23–55) |
| gender (female %) | 70.2% | |
| education (% > 10 years) | 63.2% | |
| work situation (% in regular job or education) | 68.4% | |
| marital status (% married or living together) | 49.1% | |
| BDI-II | 10.6 (8.8) | (0–36) |
| MADRS | 5.8 (4.8) | (0–22) |
| current psychotherapy | 22.8% | |
| current psychotropic medication | 24.6% | |
| number of previous episodes | 3.8 (1.9) | (1–7) |
| duration of previous hospitalization (weeks) | 9.3 (12.9) | (0–75) |
| residual symptom levels (composite score BDI-II | 0.5 (1.0) | (-0.8–4.1) |
| PTQ | 30.8 (14.5) | (0–60) |
| daily-life valence | 3.7 (0.9) | (2.4–5.9) |
| daily-life calmness | 3.4 (0.9) | (1.6–5.7) |
| daily-life energetic arousal | 3.4 (0.8) | (1.7–5.4) |
| instability of daily-life valence | 1.3 (0.9) | (0.04–3.8) |
| instability of daily-life calmness | 1.6 (1.2) | (0.2–6.6) |
| instability of daily-life energetic arousal | 1.6 (1.1) | (0.2–5.0) |
| daily-life rumination | 1.6 (1.1) | (0–4.2) |
| instability of state rumination | 2.9 (2.6) | (0–9.2) |
1 BDI-II BeckDepressionInventory II
2 MADRS Montgomery and Asberg Depression Rating Scale
3 selective serotonin reuptake inhibitors (SSRIs): n = 4, serotonin-norepinephrine reuptake inhibitors (SNRIs): n = 5, noradrenergic and specific serotonergic antidepressant: n = 2, selective serotonin and noradrenalin reuptake inhibitor (SSNRI): n = 1, tricyclic antidepressants (TCAs): n = 1, amber: n = 1, Lithium: n = 2, atypical antipsychotic medication: n = 1; anticonvulsant: n = 1; n = 4 participants with multiple prescriptions
4 PTQ Perseverative Thinking Questionnaire
5AA Ambulatory Assessment
6averaged across assessment days.
Simple and multiple regression models for time to relapse, chronicity, and depression scores (T2, T3) in remitted depressed patients (rMDD).
| outcome variables | shorter time to relapse after T1 | chronicity/ % of weeks with significant symptoms after T1 | composite depression score (BDI-II/MADRS) T2, T3 | |||
|---|---|---|---|---|---|---|
| predictors | ||||||
| B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | B (SE) | |
| Age | 0.003 (0.019) | - | - 0.001 (0.014) | - | 0.007 (0.010) | - |
| sex (1 = m, 2 = f) | -0.518 (0.388) | - | - 0.547 (0.313) | - | 0.236 (0.239) | - |
| education level (0 = ≥10y, 1 = <10 y) | 0.238 (0.040) | - | 0.074 (0.304) | - | -0.034 (0.229) | - |
| medication use (0 = no, 1 = yes) | -0.116 (0.437) | - | -0.388 (0.337) | - | -0.366 (0.303) | - |
| residual symptoms at baseline | - | |||||
| 0.020 (0.014) | - | - | ||||
| valence | -0.289 (0.240) | - | -0.293 (0.160) | - | - | |
| energetic arousal | -0.189 (0.248) | - | - | - | ||
| calmness | -0.291 (0.242) | - | -0.202 (0.169) | - | - | |
| instability of valence | 0.213 (0.159) | - | 0.209 (0.118) | - | ||
| instability of energetic arousal | 0.156 (0.147) | - | 0.165 (0.129) | - | 0.064 (0.099) | - |
| instability of calmness | 0.229 (0.131) | - | 0.214 (0.119) | - | 0.089 (0.091) | - |
| rumination | 0.275 (0.162) | - | 0.185 (0.132) | - | - | |
| rumination*time | - | - | - | - | ||
| instability of daily-life rumination | - | 0.093 (0.057) | - | |||
a cox regression model
b linear regression model
c mixed models (hierarchical linear models)
d AA Ambulatory Assessment variable
e model includes main effects and interaction effect of predictor and time
f all multiple models included subsample status as a covariate
*** p < .001
** p < .01
* p < .05
Fig 2Estimated survival curve for remaining in remission in rMDD individuals with low and high instability of affective valence at baseline.
(A) rMDD participants with low instability of affective valence (n = 28). (B) rMDD participants with high instability of affective valence (n = 28). Median split for illustrative purposes. Data from one participant were missing.